ID: ALA2347830

Max Phase: Preclinical

Molecular Formula: C17H19ClN2O3S

Molecular Weight: 366.87

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(=O)N1CCN(Cc2ccc(Oc3ccc(Cl)cc3O)s2)CC1

Standard InChI:  InChI=1S/C17H19ClN2O3S/c1-12(21)20-8-6-19(7-9-20)11-14-3-5-17(24-14)23-16-4-2-13(18)10-15(16)22/h2-5,10,22H,6-9,11H2,1H3

Standard InChI Key:  CCLFZGFJBOAQQD-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 366.87

Molecular Weight (Monoisotopic): 366.0805

AlogP: 3.56

#Rotatable Bonds: 4

Polar Surface Area: 53.01

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.64

CX Basic pKa: 6.03

CX LogP: 2.73

CX LogD: 2.65

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.90

Np Likeness Score: -1.08

References

1. Cheng G, Muench SP, Zhou Y, Afanador GA, Mui EJ, Fomovska A, Lai BS, Prigge ST, Woods S, Roberts CW, Hickman MR, Lee PJ, Leed SE, Auschwitz JM, Rice DW, McLeod R..  (2013)  Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.,  23  (7): [PMID:23453069] [10.1016/j.bmcl.2013.02.019]

Source

Source(1):

• Scientific Literature